Eutilex "Received Notification from MFDS to Resume Domestic Phase 1/2 Trial of App B&T Cell"
[Asia Economy Reporter Geum Bo-ryeong] Eutilex announced on the 21st that it received notification from the Ministry of Food and Drug Safety to resume the domestic Phase 1/2 clinical trial of the anticancer drug 'AppB&T Cell'.
Hot Picks Today
"Samsung and Hynix Were Once for the Underachievers"... Hyundai Motor Employee's Lament
- "Sold Everything Fearing Bankruptcy, Then It Soared 3,900 Times: How a Stock Once Feared for Delisting Became an AI Powerhouse"
- "All Major Corporations Could Leave"... Business Community Fears Overseas Factory Relocation Due to Strike Risks
- Fiscal Pressure Mounts Amid Surging U.S. Treasury Yields...Exceeds Supplementary Budget Estimate by 0.04%p
- "That? It's Already Stashed" Nightlife Scene Crosses the Line [ChwiYak Nation] ③
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
